The OIG report is evidence that the Orphan Drug Act is not working as intended. OIG looked at the 20 drugs in Part B and Part D with the highest expenditures and found that 22 of these 40 were orphan drugs. Interestingly, 15 of those 22 orphan drugs also had approved non-orphan indications, making them partial orphan drugs (drugs approved to treat both rare and common diseases).
Pharmaceutical Care
Management Association
505 9th Street NW, 10th Floor, Washington, DC 20004
© 2025 PCMA. All Rights Reserved.